[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-001", "question": "A 74-year-old man presents with heart failure with preserved ejection fraction (HFpEF) and bilateral carpal tunnel syndrome. Echocardiography reveals a granular 'sparkling' appearance of the myocardium and increased wall thickness. A technetium-99m pyrophosphate (PYP) scan shows Grade 3 cardiac uptake (uptake > rib uptake). Serum immunofixation reveals a small IgG lambda monoclonal protein, and serum free light chain ratio is 1.8. Which of the following is the most appropriate next step in management to confirm the diagnosis?", "options": ["Initiate tafamidis therapy", "Perform TTR genetic testing", "Endomyocardial biopsy", "Abdominal fat pad aspiration", "Initiate bortezomib, cyclophosphamide, and dexamethasone"], "answer": "C", "answer_index": 2, "explanation": "While Grade 2/3 PYP uptake is highly specific for ATTR cardiac amyloidosis, this specificity drops significantly in the presence of a monoclonal gammopathy (MGUS). AL amyloidosis can occasionally show uptake on PYP scans. Therefore, in a patient with a positive PYP scan AND a monoclonal protein, a tissue biopsy (endomyocardial is gold standard if non-cardiac biopsy is negative or to avoid sampling error) is mandatory to distinguish ATTR from AL amyloidosis before starting treatment.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with signs and symptoms highly suggestive of cardiac amyloidosis (HFpEF, bilateral carpal tunnel syndrome, granular sparkling on echo, increased wall thickness). The Technetium-99m pyrophosphate (PYP) scan shows Grade 3 uptake, which is strongly suggestive of Transthyretin (ATTR) cardiac amyloidosis. However, the diagnostic algorithm for non-invasive diagnosis of ATTR amyloidosis requires the exclusion of a monoclonal protein (evidence of a plasma cell dyscrasia).\n\nThis patient has a monoclonal protein identified (IgG lambda and elevated free light chain ratio). The presence of a monoclonal protein indicates the possibility of Light Chain (AL) amyloidosis, which is a hematologic emergency. Although Grade 3 PYP uptake is typical for ATTR, AL amyloidosis can occasionally show uptake on bone-avid tracer scans. Furthermore, Monoclonal Gammopathy of Undetermined Significance (MGUS) is common in the elderly population (who are also at risk for ATTR wild-type), so the patient could have ATTR amyloidosis with incidental MGUS, or AL amyloidosis.\n\nNon-invasive criteria (Positive Scan + Negative Serology) are not met. Therefore, histological confirmation (biopsy) with amyloid typing (using mass spectrometry or immunohistochemistry) is mandatory to confirm the diagnosis and distinguish between ATTR and AL amyloidosis.\n\nWhile an abdominal fat pad aspiration (Option D) is less invasive, its sensitivity for ATTR amyloidosis (particularly wild-type) is low (approx. 15-30%). A negative fat pad result would not rule out amyloidosis, and an endomyocardial biopsy would still be required. Given the strong evidence of cardiac involvement (Grade 3 uptake, echo findings) and the need for a definitive diagnosis to guide potentially disparate treatments (chemotherapy for AL vs. tafamidis for ATTR), an endomyocardial biopsy is the most direct and appropriate step to confirm the nature of the cardiac deposits.\n\nInitiating therapy (Option A or E) is inappropriate without a confirmed diagnosis. Genetic testing (Option B) is performed after the diagnosis of ATTR is confirmed to distinguish between hereditary and wild-type forms, but it does not rule out AL amyloidosis.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-002", "question": "A 24-year-old male presents with recurrent fevers, livedo racemosa, and acute left hemiparesis. MRI shows a lacunar infarct in the internal capsule. Angiography reveals a 'beads-on-a-string' appearance in the mesenteric and renal arteries. Laboratory evaluation shows low serum IgM and IgG levels. Genetic testing confirms a biallelic loss-of-function mutation in ADA2. Which of the following is the most appropriate maintenance therapy?", "options": ["Cyclophosphamide", "Rituximab", "Etanercept", "Prednisone monotherapy", "Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "The patient has Deficiency of Adenosine Deaminase 2 (DADA2), which mimics Polyarteritis Nodosa (PAN) but is distinct due to its association with early-onset strokes and hypogammaglobulinemia. Unlike classic PAN, which is treated with cyclophosphamide, DADA2 is driven by TNF-alpha dysregulation. TNF inhibitors (like etanercept) are the treatment of choice and are highly effective in preventing recurrent strokes, whereas cyclophosphamide is often ineffective.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient's presentation of recurrent fevers, livedo racemosa, early-onset lacunar stroke, and \"beads-on-a-string\" angiography (resembling polyarteritis nodosa) combined with low immunoglobulins and biallelic *ADA2* mutations is diagnostic of Deficiency of Adenosine Deaminase 2 (DADA2).\n\nDADA2 is an autoinflammatory disease characterized by a vasculopathy that affects small- and medium-sized arteries, leading to ischemic strokes, systemic inflammation, and mild immunodeficiency. Historically, these patients were often misdiagnosed with Polyarteritis Nodosa (PAN).\n\nThe most significant clinical risk in DADA2 is recurrent ischemic stroke. While corticosteroids and cyclophosphamide (standard treatments for PAN) have been used, they do not effectively prevent stroke recurrence in DADA2 patients. Clinical studies and case series have established that Anti-TNF agents (such as etanercept, adalimumab, or infliximab) are the treatment of choice for the vasculitis phenotype of DADA2. They have been shown to be highly effective in controlling inflammation and, crucially, virtually eliminating the risk of recurrent strokes.\n\nHematopoietic stem cell transplantation (HSCT) may be considered for patients with severe bone marrow failure or severe immunodeficiency, but for the vasculitis and stroke prevention described in this scenario, anti-TNF therapy is the first-line maintenance therapy.\n\n*   Option A (Cyclophosphamide): Used for idiopathic PAN but less effective for stroke prevention in DADA2.\n*   Option B (Rituximab): Not a standard therapy for DADA2.\n*   Option C (Etanercept): An anti-TNF agent, which is the standard maintenance therapy to prevent strokes in DADA2.\n*   Option D (Prednisone monotherapy): Not effective for long-term maintenance or stroke prevention.\n*   Option E (Plasma exchange): Not a standard maintenance therapy.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-003", "question": "A 64-year-old male presents with a 1-year history of progressive gait instability, dysarthria, and dysphagia. His wife reports he has severe insomnia, stridor during sleep, and acts out his dreams. Polysomnography confirms obstructive sleep apnea and complex behaviors during both REM and NREM sleep. MRI brain is unremarkable. Which of the following antibodies is most likely to be positive?", "options": ["Anti-Hu", "Anti-Ma2", "Anti-LGI1", "Anti-IgLON5", "Anti-DPPX"], "answer": "D", "answer_index": 3, "explanation": "Anti-IgLON5 disease is a distinct tauopathy characterized by a unique sleep disorder (parasomnias in both REM and NREM sleep, stridor, OSA) combined with bulbar dysfunction and gait instability. While Anti-Ma2 is associated with brainstem/diencephalic involvement and sleepiness, the specific combination of stridor, NREM parasomnias, and bulbar palsy is pathognomonic for Anti-IgLON5.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The clinical presentation described is characteristic of anti-IgLON5 disease. This is a recently described neurological disorder associated with antibodies against IgLON5, a neuronal cell adhesion molecule.\n\nThe condition presents with a distinct cluster of symptoms, most notably:\n1.  Sleep dysfunction: Severe insomnia and a characteristic parasomnia often described as \"parasomnia overlap disorder,\" involving complex behaviors during both REM (REM sleep behavior disorder) and NREM sleep. Sleep-disordered breathing, particularly stridor and obstructive sleep apnea, is a hallmark feature.\n2.  Bulbar dysfunction: Dysphagia and dysarthria are very common.\n3.  Gait instability: Patients often have gait difficulties, which may resemble parkinsonism or ataxia.\n\nThe combination of progressive bulbar symptoms, gait instability, and the specific sleep architecture abnormalities (stridor, REM/NREM parasomnias) points strongly to anti-IgLON5 over the other autoimmune encephalitis syndromes listed.\n\n*   Anti-Hu is typically associated with paraneoplastic sensory neuronopathy or encephalomyelitis.\n*   Anti-Ma2 is associated with diencephalic/brainstem encephalitis (often with vertical gaze palsy and hypersomnia).\n*   Anti-LGI1 is associated with limbic encephalitis and faciobrachial dystonic seizures.\n*   Anti-DPPX is associated with CNS hyperexcitability (myoclonus, tremor) and severe gastrointestinal symptoms (diarrhea/weight loss).\n\nThe answer is (D)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-004", "question": "A 68-year-old male presents with fever of unknown origin, 15 kg weight loss, and fatigue 4 years after undergoing aortic valve replacement. Labs reveal pancytopenia and elevated liver enzymes. TTE and TEE show no vegetations. PET-CT demonstrates hypermetabolic activity in the spleen and bone marrow. Bone marrow biopsy reveals non-caseating granulomas. Standard blood cultures are negative. Which of the following is the most likely etiology?", "options": ["Sarcoidosis", "Culture-negative endocarditis (HACEK group)", "Mycobacterium chimaera", "Tropheryma whipplei", "Late-onset prosthetic valve thrombosis"], "answer": "C", "answer_index": 2, "explanation": "This is the classic presentation of disseminated *Mycobacterium chimaera* infection associated with contaminated heater-cooler units used during cardiopulmonary bypass. The incubation period can be several years. It presents with systemic symptoms, cytopenias, and granulomatous inflammation (often misdiagnosed as sarcoidosis). Diagnosis requires specific mycobacterial blood cultures or tissue PCR.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical presentation describes a patient with disseminated granulomatous disease (fever, significant weight loss, pancytopenia, hepatic involvement, and non-caseating granulomas in the bone marrow). The key historical feature is the aortic valve replacement (AVR) performed 4 years prior.\n\nThis scenario is characteristic of disseminated infection with Mycobacterium chimaera, a slow-growing non-tuberculous mycobacterium (part of the *Mycobacterium avium* complex). There has been a global outbreak of *M. chimaera* infections linked to contaminated heater-cooler units used during cardiopulmonary bypass surgery.\n\nKey features supporting this diagnosis include:\n1.  Latency: Symptoms typically develop months to years (often 1 to 5+ years) after cardiac surgery.\n2.  Disseminated Disease: It often manifests with constitutional symptoms (fever, fatigue, weight loss) and extra-cardiac involvement (splenomegaly, hepatitis, nephritis, bone marrow infiltration causing pancytopenia).\n3.  Cardiac Findings: Echocardiography often reveals no vegetations or only minor findings, as the infection frequently involves the sewing ring or perivalvular tissue rather than forming large leaflets vegetations.\n4.  Histology: Biopsies of affected tissues (liver, bone marrow, lymph nodes) typically show non-caseating granulomas, which can easily be misdiagnosed as sarcoidosis.\n5.  Microbiology: Standard blood cultures are negative; specific mycobacterial cultures or molecular testing are required.\n\nWhile Sarcoidosis (Option A) presents with non-caseating granulomas, the history of open-heart surgery makes *M. chimaera* the critical diagnosis to identify. HACEK endocarditis and Whipple's disease can cause culture-negative endocarditis but do not fit the timeline and disseminated granulomatous profile as precisely as *M. chimaera* in this post-surgical context.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-005", "question": "A 31-year-old female presents with amenorrhea 4 months after a full-term delivery. Ultrasound reveals a 4 cm echogenic mass in the myometrium. Serum beta-hCG is 120 IU/L. Immunohistochemistry of a biopsy specimen shows diffuse positivity for human placental lactogen (hPL) and Ki-67 index of 15%. Staging workup is negative for metastasis. What is the treatment of choice?", "options": ["Methotrexate and Folinic Acid", "Actinomycin D", "EMA-CO regimen", "Hysterectomy", "Pembrolizumab"], "answer": "D", "answer_index": 3, "explanation": "The diagnosis is Placental Site Trophoblastic Tumor (PSTT), distinguished from choriocarcinoma by low beta-hCG, strong hPL positivity, and origin from intermediate trophoblasts. Unlike choriocarcinoma, PSTT is relatively resistant to chemotherapy. For localized (Stage I) disease, hysterectomy is the primary and definitive treatment. Chemotherapy is reserved for metastatic or high-risk disease.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient presents with a uterine mass, low serum beta-hCG, and amenorrhea following a full-term pregnancy. The key to the diagnosis lies in the immunohistochemistry findings: biochemical markers for Placental Site Trophoblastic Tumor (PSTT) are distinct from Choriocarcinoma.\n\n1.  Diagnosis: The biopsy shows diffuse positivity for human placental lactogen (hPL).\n    *   PSTT arises from intermediate trophoblasts and is characterized by diffuse hPL expression and low beta-hCG levels (often < 1000 IU/L). Ki-67 is typically lower (10-30%) compared to choriocarcinoma (>90%).\n    *   Choriocarcinoma is derived from cytotrophoblasts and syncytiotrophoblasts, typically shows high beta-hCG, and immunohistochemistry would show diffuse beta-hCG and only focal hPL positivity.\n    *   Epithelioid Trophoblastic Tumor (ETT) also arises from intermediate trophoblasts but generally shows focal hPL and positive p63. The diffuse hPL favors PSTT.\n\n2.  Management:\n    *   PSTT is relatively chemo-resistant compared to other forms of Gestational Trophoblastic Neoplasia (GTN) like choriocarcinoma.\n    *   Because of this lesser sensitivity to chemotherapy and the tendency for the tumor to remain confined to the uterus for a period (slow growth, late metastasis), hysterectomy is the primary treatment for localized (non-metastatic) disease.\n    *   Chemotherapy (often multi-agent regimens like EMA/EP) is reserved for metastatic disease or high-risk cases (e.g., interval from pregnancy > 4 years), usually in conjunction with surgery. Methotrexate or Actinomycin D monotherapy is used for low-risk choriocarcinoma or invasive mole but is ineffective for PSTT.\n\nSince the staging workup is negative for metastasis (Stage I), the definitive treatment is surgical resection.\n\nThe answer is (D)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-006", "question": "A 40-year-old male with a known diagnosis of Brugada syndrome presents to the ER in electrical storm, having received 4 appropriate ICD shocks for ventricular fibrillation in the past hour. He is currently conscious but anxious. Vital signs are BP 110/70, HR 90. Which pharmacologic agent is most appropriate to suppress the arrhythmia?", "options": ["Intravenous Amiodarone", "Intravenous Lidocaine", "Intravenous Isoproterenol", "Intravenous Procainamide", "Intravenous Metoprolol"], "answer": "C", "answer_index": 2, "explanation": "In Brugada syndrome electrical storm, the goal is to decrease the ST-segment elevation and dispersion. Isoproterenol (a beta-agonist) increases heart rate and calcium current, normalizing the ST segment and suppressing VF. Quinidine is the oral alternative. Amiodarone, beta-blockers, and sodium channel blockers (Procainamide, Lidocaine) are contraindicated or ineffective as they can unmask or exacerbate the Brugada pattern.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Here is the step-by-step reasoning for the correct answer:\n\n1.  Identify the Clinical Scenario: The patient has Brugada syndrome and is experiencing an electrical storm (defined as 3 or more episodes of sustained ventricular tachycardia/fibrillation or appropriate ICD shocks within 24 hours).\n\n2.  Understand the Pathophysiology: Brugada syndrome is an inherited channelopathy, often involving a widening of the action potential notch in the right ventricular outflow tract epicardium. Arrhythmias in Brugada syndrome are often pause-dependent or bradycardia-dependent. Phase 2 reentry is a proposed mechanism, driven by an outward potassium current ($I_{to}$) that is unopposed due to reduced sodium ($I_{Na}$) or calcium currents.\n\n3.  Evaluate Pharmacologic Options:\n    *   A. Amiodarone: While useful in ischemic VT storms, amiodarone is not the first-line choice for Brugada syndrome and has variable efficacy. It possesses sodium-channel blocking properties which is theoretically undesirable.\n    *   B. Lidocaine: This is a Class IB sodium channel blocker. While less dangerous than Class IC agents, sodium channel blockade is the mechanism used to *provoke* the Brugada ECG pattern. It does not treat the underlying mechanism of the storm effectively.\n    *   C. Isoproterenol: This is a beta-adrenergic agonist. It works by increasing the heart rate and increasing the L-type calcium current ($I_{Ca-L}$). Augmenting the calcium current restores the action potential dome in the epicardium, reducing the transmural dispersion of repolarization that leads to arrhythmias. It is the guideline-recommended first-line pharmacologic therapy for electrical storm in Brugada syndrome.\n    *   D. Procainamide: This is a Class IA sodium channel blocker. It is used in provocative testing to *diagnose* Brugada syndrome (unmasking the ECG pattern). Administering this would likely worsen the arrhythmia and is contraindicated.\n    *   E. Metoprolol: Beta-blockers slow the heart rate. Since Brugada syndrome arrhythmias are often bradycardia-dependent or vagally mediated (occurring at rest or sleep), beta-blockers can exacerbate the condition and are generally avoided in the acute setting of a storm.\n\n4.  Conclusion: Intravenous Isoproterenol is the specific antidote for electrical storm in Brugada syndrome because it augments calcium influx and increases heart rate, stabilizing the cardiac membrane potential.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-007", "question": "A 32-year-old female presents with subacute confusion, bilateral hearing loss, and visual field deficits. MRI brain shows multiple T2 hyperintense lesions in the corpus callosum ('snowballs') and periventricular white matter. Fluorescein angiography reveals multiple branch retinal artery occlusions (BRAO). CSF shows mild pleocytosis and elevated protein but no oligoclonal bands. What is the most likely diagnosis?", "options": ["Multiple Sclerosis", "CADASIL", "Susac Syndrome", "Primary CNS Angiitis", "Mitochondrial Encephalomyopathy (MELAS)"], "answer": "C", "answer_index": 2, "explanation": "Susac Syndrome is a rare autoimmune endotheliopathy characterized by the clinical triad of encephalopathy, branch retinal artery occlusions (BRAO), and sensorineural hearing loss. The MRI finding of 'snowball' lesions in the corpus callosum is highly characteristic. It is often misdiagnosed as MS, but the presence of BRAO and callosal lesions (rather than callososeptal interface lesions) distinguishes it.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with the classic clinical triad of Susac syndrome: encephalopathy (confusion), branch retinal artery occlusions (visual field deficits), and hearing loss.\n\n1.  Demographics: Susac syndrome predominantly affects young women (aged 20-40).\n2.  Clinical Triad:\n    *   Brain: Encephalopathy manifesting as behavioral changes, memory loss, or confusion.\n    *   Retina: Branch retinal artery occlusions (BRAO), which causes visual field deficits. These are confirmed by fluorescein angiography.\n    *   Cochlea: Sensorineural hearing loss (often low to mid-frequency).\n3.  Imaging: MRI of the brain typically shows multifocal T2/FLAIR hyperintense lesions. A hallmark finding is the presence of lesions in the central portion of the corpus callosum, often described as \"snowballs\". In contrast to Multiple Sclerosis (where lesions affect the callososeptal interface), Susac lesions tend to be central within the corpus callosum.\n4.  CSF Findings: Mild lymphocytic pleocytosis and elevated protein are common, while oligoclonal bands are typically absent (unlike in MS).\n\nWhy other options are incorrect:\n*   Multiple Sclerosis (A): While it affects the corpus callosum and white matter, the lesions are perivenular (\"Dawson's fingers\") and involve the callososeptal interface. Visual symptoms are usually due to optic neuritis, not BRAO. Oligoclonal bands are present in >85% of cases.\n*   CADASIL (B): This is a genetic small vessel disease marked by migraines and strokes. MRI classically shows anterior temporal lobe involvement. It does not present with BRAO or this specific triad.\n*   Primary CNS Angiitis (D): This vasculitis is restricted to the CNS and does not typically involve the retina (BRAO) or cochlea to form this specific triad.\n*   MELAS (E): Stroke-like episodes in MELAS do not respect vascular territories, and retinal findings are usually pigmentary retinopathy, not BRAO.\n\nThe answer is (C)\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-008", "question": "A 29-year-old male who has sex with men presents with severe proctitis, tenesmus, and rectal bleeding. Rectal swab NAAT is positive for *Chlamydia trachomatis*. He was treated with Doxycycline 100 mg BID for 7 days with no improvement. His partner recently returned from Europe. Which of the following is the most appropriate management?", "options": ["Repeat Doxycycline 100 mg BID for 7 days", "Azithromycin 1 g single dose", "Ceftriaxone 500 mg IM single dose", "Extend Doxycycline 100 mg BID to complete a 21-day course", "Moxifloxacin 400 mg daily for 14 days"], "answer": "D", "answer_index": 3, "explanation": "Severe proctitis in MSM with a positive Chlamydia test should raise suspicion for Lymphogranuloma Venereum (LGV), caused by L1, L2, or L3 serovars. LGV requires a prolonged course of doxycycline (21 days) compared to non-LGV chlamydia (7 days). Standard treatment failure and severe symptoms (bleeding/tenesmus) strongly support a diagnosis of LGV.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient is a male who has sex with men (MSM) presenting with severe proctitis (rectal pain, discharge, tenesmus, bleeding) and a rectal swab positive for *Chlamydia trachomatis*. The severity of the symptoms (specifically tenesmus and bleeding), the patient's demographic, and the lack of response to the standard 7-day course for uncomplicated chlamydia strongly suggest Lymphogranuloma Venereum (LGV). LGV is caused by the invasive L1, L2, and L3 serovars of *C. trachomatis*. Conventional chlamydia (serovars D-K) typically causes mild or asymptomatic proctitis.\n\nEpidemiologically, outbreaks of LGV proctitis are prevalent among MSM populations in North America and Western Europe (noted by the partner's travel).\n\nAccording to CDC guidelines, patients with clinical signs of LGV (such as severe proctocolitis) and a positive NAAT for *C. trachomatis* should be treated for LGV while genotyping results are pending (if available). The recommended treatment for LGV is Doxycycline 100 mg orally twice a day for 21 days. Since the patient has already completed a 7-day course, the appropriate management is to extend the therapy to complete the full 21-day regimen.\n\n*   Option A: A total of 14 days is insufficient for LGV.\n*   Option B: A single dose of Azithromycin is indicated for uncomplicated urogenital chlamydia but is less effective for rectal chlamydia and insufficient for LGV.\n*   Option C: Ceftriaxone is the treatment for Gonorrhea.\n*   Option E: Moxifloxacin is the treatment for *Mycoplasma genitalium*.\n\nThe answer is (D)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-009", "question": "A 70-year-old man is evaluated for macrocytic anemia (MCV 105), thrombocytopenia, and recurrent inflammation of the ear and nose cartilage. He also has pulmonary infiltrates. Bone marrow biopsy demonstrates hypercellularity with vacuolization of myeloid and erythroid precursor cells. Genetic sequencing identifies a somatic mutation in *UBA1*. What is the diagnosis?", "options": ["Relapsing Polychondritis", "Myelodysplastic Syndrome (MDS)", "VEXAS Syndrome", "Sweet Syndrome", "Granulomatosis with Polyangiitis"], "answer": "C", "answer_index": 2, "explanation": "VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described disorder caused by somatic mutations in *UBA1*. It connects inflammatory features (polychondritis, vasculitis, infiltrates) with hematologic features (macrocytic anemia, vacuoles in marrow precursors). While it mimics relapsing polychondritis, the presence of marrow vacuoles and the *UBA1* mutation defines VEXAS.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Based on the clinical presentation and genetic findings, the correct diagnosis is VEXAS Syndrome.\n\nHere is the breakdown of the features described:\n*   Vacuoles: The bone marrow biopsy shows vacuolization of myeloid and erythroid precursor cells, a pathognomonic feature.\n*   E1 enzyme: The condition is caused by a mutation affecting the E1 ubiquitin-activating enzyme.\n*   X-linked: The gene involved is on the X chromosome, which explains why the disease predominantly affects men (like the 70-year-old patient).\n*   Autoinflammatory: The patient presents with recurrent inflammation, specifically chondritis (ear and nose inflammation) and pulmonary infiltrates.\n*   Somatic: The mutation in the *UBA1* gene is somatic (acquired), not germline.\n\nWhile the patient has features that resemble Relapsing Polychondritis (chondritis) and Myelodysplastic Syndrome (macrocytic anemia, cytopenias), the unification of these symptoms with the specific bone marrow findings and the *UBA1* mutation defines VEXAS syndrome.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-010", "question": "A 35-year-old female undergoes a cone biopsy for CIN 3. Pathology reveals invasive squamous cell carcinoma with 2 mm depth of invasion and 5 mm horizontal spread. Lymphovascular space invasion (LVSI) is extensively present. Margins are negative. Imaging shows no lymphadenopathy. She desires future fertility. According to NCCN guidelines, what is the recommended management?", "options": ["Simple trachelectomy", "Radical trachelectomy with pelvic lymph node assessment", "Conization with negative margins is sufficient", "Simple hysterectomy", "Pelvic radiation therapy"], "answer": "B", "answer_index": 1, "explanation": "The patient has Stage IA1 cervical cancer (invasion <= 3mm). However, the presence of Lymphovascular Space Invasion (LVSI) significantly increases the risk of lymph node metastasis and recurrence. Therefore, simple excision (cone) or simple trachelectomy/hysterectomy is insufficient. The recommended management for fertility preservation in IA1 with LVSI is radical trachelectomy with pelvic lymph node assessment (sentinel node or dissection).", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has Stage IA1 cervical squamous cell carcinoma (depth of invasion $\\le$ 3 mm). However, the presence of lymphovascular space invasion (LVSI) significantly alters the management compared to Stage IA1 without LVSI.\n\n1.  Staging and Risk Stratification: The diagnosis is FIGO Stage IA1 (2 mm depth). While Stage IA1 without LVSI can often be managed with conization alone (provided margins are negative), the presence of extensive LVSI increases the risk of lymph node metastasis and recurrence.\n2.  NCCN Guidelines: According to NCCN guidelines, patients with Stage IA1 cervical cancer with LVSI who desire fertility preservation require pelvic lymph node assessment. The recommended options usually include:\n    *   Radical trachelectomy with pelvic lymph node dissection.\n    *   In some updated guidelines/contexts, cone biopsy with pelvic lymph node dissection (sentinel lymph node mapping) may be considered, but lymph node assessment is mandatory.\n3.  Evaluating Options:\n    *   A. Simple trachelectomy: This procedure removes the cervix but does not address the pelvic lymph nodes. Given the LVSI, nodal assessment is required.\n    *   B. Radical trachelectomy with pelvic lymph node assessment: This is the standard finding in guidelines for Stage IA1 with LVSI (or Stage IA2) for patients valuing fertility. It addresses both the primary tumor site (with wider margins/parametrium, though the necessity of parametrectomy in IA1 is debated, the nodal assessment is non-negotiable) and the lymph nodes.\n    *   C. Conization with negative margins is sufficient: This would be the correct answer for Stage IA1 *without* LVSI. However, with LVSI, observation alone is inadequate due to the risk of nodal disease.\n    *   D. Simple hysterectomy: This is not fertility-sparing.\n    *   E. Pelvic radiation therapy: This is not fertility-sparing.\n\nTherefore, the only fertility-sparing option listed that adequately addresses the risk posed by LVSI (via lymph node assessment) is Radical Trachelectomy.\n\nThe answer is (B)"}]